Literature DB >> 3884747

The effect of administration rate on cisplatin-induced emesis.

N S Jordan, P K Schauer, A Schauer, C Nightingale, G Golub, R S Martin, H M Williams.   

Abstract

In an attempt to determine the influence of administration time on cisplatin-induced emesis, 20 adults previously untreated with cisplatin were enrolled into this double-blind study. Twenty patients were randomly assigned to receive high-dose cisplatin (greater than 100 mg/m2) either by a one-hour infusion or by an eight-hour infusion. All patients received antiemetic therapy with metoclopramide 2 mg/kg intravenously one-half hour before cisplatin administration, and 1 1/2, 3 1/2, 5 1/2, and 8 1/2 hours after cisplatin administration. Patients in the eight-hour infusion group experienced significantly fewer emesis episodes than did patients in the one-hour infusion group. The median of emesis episodes in the eight-hour group was one (range, 0 to 2) and in the one-hour group was three (range, 0 to 8). In patients receiving high-dose cisplatin plus metoclopramide, increasing the administration time from one hour to eight hours resulted in a small but significant decrease in emesis episodes. The cisplatin infusion rate should be considered as a variable in cisplatin-antiemetic trials.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3884747     DOI: 10.1200/JCO.1985.3.4.559

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life.

Authors:  Nibal Abunahlah; Mesut Sancar; Faysal Dane; Mustafa Kerem Özyavuz
Journal:  Int J Clin Pharm       Date:  2016-10-28

2.  A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response.

Authors:  J Carmichael; B M Cantwell; C M Edwards; B D Zussman; S Thompson; W G Rapeport; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Precise quantitative evaluation of pharmacokinetics of cisplatin using a radio-platinum tracer in tumor-bearing mice.

Authors:  Honoka Obata; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Katsuyuki Minegishi; Kotaro Nagatsu; Mikako Ogawa; Ming-Rong Zhang
Journal:  Nucl Med Commun       Date:  2022-09-19       Impact factor: 1.698

Review 4.  Antiemetics in cancer chemotherapy: historical perspective and current state of the art.

Authors:  M Tonato; F Roila; A Del Favero; E Ballatori
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

5.  Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer.

Authors:  P A Reece; I Stafford; M Davy; R Morris; S Freeman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 6.  Optimum management of nausea and vomiting in cancer chemotherapy.

Authors:  P L Triozzi; J Laszlo
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

Review 7.  [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

Authors:  A Du Bois
Journal:  Med Klin (Munich)       Date:  1998-01

8.  The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.

Authors:  J A Green; S W Watkin; P Hammond; J Griggs; T Challoner
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.